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ABSTRACT: In recent years, cardiac glycosides (CGs) have
been investigated as potential antiviral and anticancer drugs.
Digitoxigenin (DIG) and other CGs have been shown to bind
and inhibit Na+/K+-adenosinetriphosphatase (ATPase).
Tumor cells show a higher expression rate of the Na+/K+-
ATPase protein or a stronger affinity towards the binding of
CGs and are therefore more prone to CGs than non-tumor
cells. Cancer imaging techniques using radiotracers targeted at
specific receptors have yielded successful results. Technetium-
99m (99mTc) is one of the radionuclides of choice to
radiolabel pharmaceuticals because of its favorable physical
and chemical properties along with reasonable costs. Herein,
we describe a new Na+/K+-ATPase targeting radiotracer
consisting of digitoxigenin and diethylenetriaminepentaacetic acid (DTPA), a bifunctional chelating ligand used to prepare
99mTc-labeled complexes, and its evaluation as an imaging probe. We report the synthesis and characterization of the
radiolabeled compound including stability tests, blood clearance, and biodistribution in healthy mice. Additionally, we
investigated the binding of the compound to A549 human non-small-cell lung cancer cells and the inhibition of the Na+/K+-
ATPase by the labeled compound in vitro. The 99mTc-labeled DTPA−digitoxigenin (99mTc-DTPA−DIG) compound displayed
high stability in vitro and in vivo, a fast renal excretion, and a specific binding towards A549 cancer cells in comparison to non-
tumor cells. Therefore, 99mTc-DTPA−DIG could potentially be used for non-invasive visualization of tumor lesions by means of
scintigraphic imaging.
■ INTRODUCTION
Lung cancer is considered to be one of the most aggressive
tumors with a very low survival rate; therefore, patients would
benefit from early diagnosis and treatment.1 Nuclear medicine
and radionuclides are valid strategies for early cancer detection
since they detect physiological changes in the target tissue.
Other imaging methods, such as ultrasound, computed
tomography, and magnetic resonance imaging, are especially
able to identify morphological changes.2
Cardiac glycosides (CGs), including cardenolides, are
natural products used for treating cardiac insufficiency in
humans, as they bind to and inhibit Na+/K+-adenosinetriphos-
phatase (ATPase) in the myocardium, resulting in an increased
cardiac output by enhancing the force of contraction. The
Na+/K+-ATPase is a ubiquitously expressed P-type hetero-
meric integral membrane protein complex of eukaryotic cells,
which actively transports three sodium and two potassium ions
across the cell membrane using adenosine 5′-triphosphate
(ATP) hydrolysis as the driving force.3,4 It consists of three
subunitsa catalytic α subunit, a stabilizing and activity-
modulating β subunit, and a regulatory γ subunit, also known
as an auxiliary FXYD2 protein.4,5
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Mutations and altered expression of Na+/K+-ATPase(s)
have been linked to several diseases, like Alzheimer’s disease,
diabetes mellitus, or the growth of cancer cells. Cancer-
promoting effects seem to correspond with mutations and
differences in expression rates of the α- and β-subunits of the
Na+/K+-ATPase.6 Different relative expressions of Na+/K+-
ATPase subunits further influence the susceptibility and
binding affinity to specific cardenolides.4 Lately based on the
before-mentioned results, new therapeutic applications, besides
the use of cardenolides to treat congestive heart failure, for
various other diseases, e.g., viral infection or ischemic stroke,
have been described.7,8 Recent studies have further reported
an increased susceptibility of cancer cells to cardenolides
(reviewed in refs 9−11) and their antiviral activity.7,12,13 It has
been shown that several cancer cell lines, including the A549
non-small-cell lung cancer cell line, overexpress Na+/K+-
ATPase proteins on their membrane, especially the α-subunit,
on which cardenolides like digitoxigenin (DIG) bind with high
affinity.11,14,15 For that reason, radiolabeled DIG may be an
interesting probe to identify and localize tumors or even to
monitor tumor extent.
Technetium-99m (99mTc) has often been used to label
radiopharmaceuticals, due to its suitable physical and chemical
properties, along with reasonable radionuclide cost.16 Several
chelating agents are currently used to prepare stable complexes
with 99mTc, including diethylenetriaminepentaacetic acid
(DTPA), which requires mild labeling conditions and fast
reaction rates at room temperature. This is an important
characteristic of thermosensitive compounds since they may be
degraded during the labeling process.
The purpose of this study was the evaluation of the new
compound 99mTc-DTPA−digitoxigenin (99mTc-DTPA−DIG)
as a tumor-targeting probe. To achieve this aim, DTPA−
digitoxigenin (DTPA−DIG) was synthesized and character-
ized by Fourier transform infrared (FTIR), NMR, and mass
spectrometry (MS). Subsequently, the radiolabeling efficiency
and stability were examined, and in vitro cell binding in the
A549 lung cancer cell line compared to the MRC-5 non-tumor
cell line was studied. Additionally, biodistribution was
monitored and scintigraphic images were taken in healthy
mice to estimate the pharmacokinetics of the new probe.
■ RESULTS AND DISCUSSION
Synthesis and Structural Analysis of DTPA−DIG. The
reaction was carried out in different solvents ranking from
dimethyl sulfoxide (DMSO) to pyridine and tetrahydrofuran,
to improve the product yield (Table S1). Product formation
was only observed in DMSO due to the good solubility of the
educts in this solvent (Figure 1). The isolation of the product
DTPA−DIG from the reaction medium was challenging, since
it has four free carboxyl groups and an ester linkage prone to
hydrolysis at either high or low pH values. DTPA−DIG was
isolated and purified by preparative reversed-phase high-
performance liquid chromatography (RP-HPLC) employing
mild conditions (Figure S1). Fractions containing the product
were pooled, and acetonitrile (ACN) was removed by
evaporation under reduced pressure. In the sequence, the
residual water was eliminated by lyophilization to afford
DTPA−DIG as a white amorphous solid (61% yield on molar
base). The infrared spectrum of DTPA−DIG showed a
carboxylic acid O−H stretch at 3200−2500 cm−1; an alkyl
C−H stretch at 2936−2860 cm−1; CO stretches at 1712,
1778, and 1733 cm−1, respectively, of carboxylic acid, lactone
and ester as well as a C−O strong stretch at 1213 cm−1. This
last band demonstrates the presence of an ester linkage in
DTPA−DIG (Figure S2). MS spectra were acquired for the
protonated molecular ion MH+ at m/z 750.6 compatible with
the chemical formula of C37H55N3O13 from the monoester
DTPA−DIG (Figure S3). The 1H NMR spectrum of DTPA−
DIG showed the methylene protons of the DTPA group at the
interval δ 2.82−3.63 and all protons of the aglycone
digitoxigenin (Figures 1 and S4, and Table 1). The assignment
of the resonance signals was confirmed by data from the
heteronuclear single quantum coherence (HSQC) spectrum.
Two doublets centered at δ 4.98 and 4.88 (d, J21a,21b = 17.5
Hz) were ascribed to the geminal coupling of the methylene
protons at C-21. The C-3 methine proton resonates at δ 5.03, a
downfield shifted-value in comparison to H3α of the free
aglycone, due to the ester linkage with the DTPA group
(Figures S4 and S5a,b). The HSQC spectrum was very useful
to determine the 1H/13C one-bond shift correlations of all
hydrogen-bearing carbon atoms in DTPA−DIG. Complete
1H/13C one-bond shift correlations of all protonated carbon
atoms are presented in Table 1 (Figure S5a,b). The 1H−1H
correlated spectroscopy (COSY) spectrum was useful for
assigning the hydrogen resonances of DTPA−DIG (Figure
S6a−c). The C-3 methine proton (δ 5.03) showed cross-peaks
with the methylene hydrogens linked to C-2 (δ 1.50 and 1.61)
and C-4 (δ 1.33 and 1.94), whereas the C-17 methine proton
(δ 2.73) exhibited correlation spots with C-16 methylene
protons (δ 2.05 and 1.81) (Figure S6). The 13C NMR
spectrum of DTPA−DIG showed the resonance signals of 37
atoms (Table 1 and Figure S7), which were identified as two
methyl, nineteen methylene, and six methine carbon atoms by
Figure 1. Chemical synthesis of DTPA−DIG. DIG (0.29 mmol) was used as a substrate, DMSO was used as a solvent, and DMAP (0.22 mmol)
was added as a catalyst. The reaction was stirred under calcium chloride protection for 8 h at 65 °C.
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the distortionless enhancement by polarization transfer
(DEPT)-135 experiment (Figure S8), along with ten
quaternary carbons. The signals at δ 176.3 and 174.0 were
ascribed, respectively, to C-20 and C-23 of the α,β-unsaturated
lactone ring. The carbonyls at C-8′, C-10′, and C-14′ resonate
with the same chemical shift value, at δ 172.5, while the signals
at δ 170.4 and 169.8 were ascribed to C1′ and C-12′ carbonyls
(DTPA group), respectively. The downfield chemical shift
values of C-3, C-14, and C-21 were due to the presence of
geminal oxygen functionalities on these carbon atoms. The
heteronuclear multiple bond correlation (HMBC) experiment
was useful for the assignments presented in Table 1 (Figure
S9a−f). Nuclear Overhauser enhancement spectroscopy
(NOESY) data, coupling constants, and comparison with
literature records17 were used to distinguish the diastereotopic
protons within the methylene groups, which exhibited
characteristic patterns for axially or equatorially located
hydrogens (Table 1). Hence, NOESY depicted spatial
interactions between the C-3 methine proton (δ 5.03) and
C-2′ methylene (δ 3.53) hydrogens. These NOESY observa-
tions indicated that C-3 oxygen was bonded to C-1′ through
an ester linkage (Figure S10a−c). The presence of a single
ester bond in the compound DTPA−DIG was also supported
by 1H, 13C, mass spectral, and infrared data,17 as discussed
above.
99mTc Labeling of DTPA−DIG, Radiochemical Purity,
and in Vitro Stability. DTPA−DIG was radiolabeled with
99mTc in the presence of stannous chloride (SnCl2) as a
reducing agent. To evaluate the effect of the reducing agent on
the labeling process, three different amounts of the reagent
(200, 270, 330 μg) were tested, and the radiochemical purities
were determined.
Thin-layer chromatography (TLC) over silica gel was used
to determine the radiochemical yield of the 99mTc-DTPA−
DIG, employing two distinct eluent systems (acetone or glacial
acetic acid/water 15:85, v/v). The radiolabeling reaction can
yield 99mTcO4
− and 99mTcO2.
99mTcO4
− migrated with the
solvent front in both TLC systems, glacial acetic acid/water
(15:85, v/v) and acetone (Rf = 0.9−1.0), whereas the
radiocolloids (99mTcO2) remained immobilized at the point
of application in both solvents (Rf = 0.0).
99mTc-DTPA−DIG
showed Rf values of 0.9 or 0.0 in glacial acetic acid/water
(15:85, v/v) or in acetone as eluents. High radiochemical
yields play a crucial role in radiopharmaceutical applications
since the presence of radiochemical impurities has to be
limited as they cause images of low quality and they might also
accumulate in the thyroid and stomach as well as in the liver
and spleen.2 Ideally, radiopharmaceuticals should be at least
90% pure, in terms of radioactivity species.18 The use of 200 μg
of stannous chloride in the labeling reaction afforded a suitable
overall radiolabeling yield (95.8 ± 2.2%), whereas amounts of
270 and 330 μg led to a product with insufficient purity (68.7
± 7.2 and 77.1 ± 6.6%, respectively). The success of
radiolabeled DTPA−DIG was further evidenced by ultra-
performance liquid chromatography (UPLC)/MS analysis,
where the 99mTc-labeled compound gave signals in the negative
ion mode at m/z 820 [99mTc-DTPA−DIG − CO2 + H2O
− H]−, m/z 864 [99mTc-DTPA−DIG + H2O − H]−, and m/z
883 [99mTc-DTPA−DIG + 2H2O − H]− (Figure S11).
The stability of the labeled conjugate is also pivotal for the
successful application of a radiopharmaceutical.19 Aiming for
an in vivo administration of 99mTc-DTPA−DIG, its radio-
chemical stability was evaluated using the two distinct solvent
systems (acetone or glacial acetic acid/water 15:85, v/v)
mentioned above at 1, 2, 4, 8, and 24 h in the presence of NaCl
0.9% (w/v) solution at room temperature (23 °C) or in the
presence of plasma at 37 °C, under agitation. In both
conditions, the product including the ester bond remained
stable within the evaluated interval (Figure 2). If the isotope
chelation of radiodiagnostic agents does not remain stable for
several hours, the biodistribution and imaging data will be
unreliable.20
Table 1. 1H and 13C Chemical Shifts (ppm) for DTPA−DIG
(400 MHz for 1H and 100 MHz for 13C; DMSO-d6)
carbon/hydrogen 1H (J in Hz) 13C
1 α 1.24 30.3
β 1.51
2 α 1.50 24.4a
β 1.61
3 α 5.03 brs 70.5
4 α 1.94 29.9
β 1.33
5 β 1.59 36.7
6 α 1.19 26.4a
β 1.75
7 α 1.77 20.8b
β 1.12
8 β 1.48 40.9
9 α 1.64 34.7
10 34.8
11 α 1.35 20.9b
β 1.15
12 α 1.38 38.9
β 1.38
13 49.4
14 (β-OH) 83.7
15 α 2.08 32.2
β 1.63
16 α 2.05 (J16α,17α = 5.0 Hz) 26.1
β 1.81 (J16β,17α = 9.8 Hz)
17 α 2.73 (dd J17α,16β = 9.8 Hz) 50.2
18 0.78 s 15.7
19 0.90 s 23.5
20 176.3
21 a 4.98 (d Ja = 17.5 Hz) 73.1
b 4.88 (d Jb = 17.5 Hz)
22 5.91 s 116.2
23 173.8
1′ 170.4
2′ 3.53 brs 55.0
3′ 2.89 brs 50.2
4′ 2.89 brs 50.2
5′ 3.00 brs 51.8
6′ 3.00 brs 55.8
7′ 3.44 brs 55.0
8′ 172.5
9′ 3.44 brs 55.0
10′ 172.5
11′ 3.58 brs 55.0
12′ 169.6
13′ 3.44 brs 55.0
14′ 172.5
aValues may be interchangeable. bValues may be interchangeable. s,
singlet; brs, broad singlet; dd, doublet of doublets.
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Inhibition of Na+/K+-ATPase Activity by 99mTc-DTPA−
DIG and Specific Binding of 99mTc-DTPA−DIG towards
MRC-5 and A549 Cells. In a first step, the inhibition rate of
99mTc-DTPA−DIG against Na+/K+-ATPase activity (mixture
of α1,2,3 subunit from the porcine cortex) was evaluated at 0.1
μM, a concentration corresponding to the IC50 value of the
labeled compound against A549 cells (IC50 A549 cell line: 0.12
μM; IC50 non-tumor MRC-5 cell line: 0.78 μM; Figure S12).
Inhibition of porcine Na+/K+-ATPase (α1,2,3 subunit) was
investigated to assay the effect of the labeling solution, free
DTPA, and the labeling of DTPA−DIG on the Na+/K+-
ATPase activity in general (Figure 3). The obtained data
showed that neither the reagents in the labeling solution nor
DTPA alone has any effect on Na+/K+-ATPase activity.
However, concentrations of 0.1 μM of DIG, DTPA−DIG, and
99mTc-DTPA−DIG reduced the enzymatic activity to less than
50%. This indicated that neither DTPA nor 99mTc interfered
with the binding of DIG to the Na+/K+-ATPase α subunit and
that the interaction between the cardenolide derivative and its
target structure remains intact. This is an important and
positive result for assessing the suitability of the radiolabeled
compound as a potential imaging probe.
Cancer drug development is currently focused on the search
of specific biochemical differences between malignant and
normal cells, a strategy that is also adopted in the development
of diagnostic tools for the identification of tumor cells. Na+/
K+-ATPase is known to be the target receptor for CGs.21 This
ubiquitous enzyme belongs to the P-type ATPase family and is
involved as an integral membrane protein in transporting
sodium ions out of the cell and potassium ions into the cell,
thus helping regulate the electrochemical gradient across the
plasma membrane.22 Human Na+/K+-ATPase is composed of
four different isoforms of the α-subunit, acting as the catalytic
subunit of the Na+/K+-ATPase complex (α1, α2, α3, and α4).
Additionally, three different β-subunit isoforms and seven γ-
subunit isoforms result in great protein viability.23 The overall
expression pattern of the Na+/K+-ATPase is a possible
biomarker for cancer, as a high expression level of the α-
subunit and a low expression of the β-subunit may indicate an
increased risk for cancer.6 Keeping in mind that Na+/K+-
ATPase is a specific target for CGs and the different expression
rates of its subunits in malignant to non-malignant cells, the
protein constitutes a potential target to identify tumors or to
monitor tumor mass and growth.
Cardiac glycosides including cardenolides and their
derivatives are known to bind to the α-subunit of the Na+/
K+-ATPase, impairing the attachment of ATP and thus
disrupting the effect of the enzyme.24 Depending on the
concentration and structure of CGs, either the Na+/K+-ATPase
can be inhibited or the Na+/K+-ATPase signalosome can be
activated, both inhibiting cell proliferation and impeding cell
survival.6,25 An overexpression of the α1 subunit of the Na+/
K+-ATPase was observed in human non-small-cell lung cancer
A549 cell lines.26 The authors demonstrated26 that A549 cells,
overexpressing the α1 subunit of the Na+/K+ ATPase, are
more susceptible to selected cardiac glycosides, such as
digoxin, ouabain, and the hemisynthetic derivative of 2″-
oxovoruscharin (UNBS1450). The specific binding of
cardenolides to the overexpressed α1 subunit of A549 cells is
a promising and unique feature that led us to select this cell
line for an in vitro binding study.
Therefore, the specific binding of 99mTc-DTPA−DIG to the
human non-small-cell lung cancer A549 cell line versus the
non-tumor human fetal lung fibroblast MRC-5 cell line was
evaluated by quantifying the overall radioactivity level. The
concentration of 0.1 μM was also used for examining the
cellular binding of 99mTc-DTPA−DIG to the A549 cancer cells
and the non-tumor human fetal lung fibroblast MRC-5 cells.
The in vitro results showed a significantly higher binding of
99mTc-DTPA−DIG to A549 cells than to non-tumor MRC-5
cells. 99mTc-DTPA−DIG binding to A549 cells was reduced to
the rate of non-tumor MRC-5 cells when it was co-incubated
with a 10-fold excess of free digitoxigenin (Figure 4).
The outcomes from these experiments, i.e., the high specific
binding of 99mTc-DTPA−DIG to A549 cancer cells, low
affinity of 99mTc-DTPA to A549 cancer cells, and the inhibition
of the Na+/K+-ATPase by 99mTc-DTPA−DIG, let us conclude
that the higher specificity of DIG for the lung cancer cell line
A549 results from an increase in the expression of the Na+/K+-
ATPase. The selectivity of DIG towards the A549 cell line
compared with other cancer cell lines has been previously
described in cytotoxicity studies.27,28 A higher expression of
the Na+/K+-ATPase α1 subunit was reported for A549 cell
lines.26 . In the same direction, an increased expression of
certain subunits of Na+/K+-ATPase was found in bladder and
Figure 2. Radiochemical stability of 99mTc-DTPA−DIG in saline
(0.9% NaCl) at room temperature (23 °C) and plasma at 37 °C.
Radiochemical stability was tested up to 24 h (n = 6).
Figure 3. Inhibition of Na+/K+-ATPase activity by DIG, DTPA,
DTPA−DIG, and 99mTc-DTPA−DIG tested at 0.1 μM. Effects of
DIG, DTPA−DIG, and 99mTc-DTPA−DIG on Na+/K+-ATPase
activity were assayed with the Na+/K+-ATPase α1,2,3 subunit of
the porcine cortex. Results indicated Na+/K+-ATPase inhibition by
DIG, DTPA−DIG, and 99mTc-DTPA−DIG. However, labeling
solution, as well as DTPA alone, has no influence on the activity of
Na+/K+-ATPase.
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gastric cancer cells.29,30 An alteration in the overall Na+/K+-
ATPase activity was further described in renal carcinoma cells4
along with an increased expression of the α1 subunit of Na+/
K+-ATPase in the majority of glioblastomas, in comparison to
normal brain cells.31 In light of this higher expression rate of
the Na+/K+-ATPase and the specific binding of cardenolides to
their α subunit, developing imaging probes that are based on
the cardenolide structure seems to be a promising strategy for
tumor identification. Therefore, investigating the specific
binding of 99mTc-DTPA−DIG or 99mTc-DTPA coupled to
different cardenolides or cardenolide derivatives towards
various cancer cell lines can be a valid and prospective strategy
to evaluate their potential for tumor diagnosis. However, in a
first step for gaining more information on this newly
synthesized and labeled compound 99mTc-DTPA−DIG and
its suitability as an imaging probe, biodistribution as well as
blood clearance has to be studied in healthy mice.
Blood Clearance, Biodistribution, and Scintigraphic
Images in Healthy Mice. The radiolabeled complex showed
rapid blood clearance, with only 0.51 %ID/g at 0.5 h and a
further decrease at 2 h (Table 2). Its half-life was 11.7 min
(Figure 5).
Fast blood clearance is favorable for early imaging as
background radiation can lower imaging quality.20 Biodis-
tribution studies were conducted in healthy mice, and tissues
were analyzed at 0.5 and 2 h post-injection. Maximum uptake
was observed in the liver and intestine. The kidneys also
showed a high uptake, suggesting that renal elimination also
contributes to the radiopharmaceutical’s excretion (Table 2
and Figure S13).
A relatively low uptake in the thyroid was observed,
indicating high stability of the labeled complex.32 The
distribution in healthy mice was further analyzed by images.
High uptake rates in the kidneys, liver and mainly in the
intestine could be detected (Figure S13). Comparable low
accumulation of the labeled compound in the heart of healthy
mice can be due to the fact that rodents have a mutation in the
α1 subunit of their Na+/K+-ATPase, which makes them less
susceptible to CGs. For example, Ujvari and co-workers
showed that as a consequence of this mutation, the Na+/K+-
ATPase in rodents is 1000-fold more resistant to the
cardenolide ouabain.33 Additionally, cardiac α isoform
expression varies depending on the species. So far, the α3
subunit, which also has a high binding affinity to CGs, has been
only identified in humans, but not in rodents.34 Therefore, the
altered distribution of the isoforms in rodents might also be an
explanation for the low accumulation of 99mTc-DTPA−DIG in
the mice heart.
In the 1960s, the use of radiolabeled CGs made it possible to
detect cardiac glycosides and their metabolites in body fluids
and tissues. Studies with tritiated digoxin showed that its
clearance from the human body depends on renal excretion.35
Pharmacokinetic studies with digoxin in humans evidenced its
main adsorption into the intestine, kidneys and heart and a
major renal excretion.36 Likewise, the administration of the
99mTc-labeled ouabagenin−cysteine conjugate to guinea pig,
rabbit and rat also showed fast blood clearance and renal
elimination. For rabbits and rats, an additional high uptake in
the liver was also observed.37 CGs aglycones like ouabagenin
and digitoxigenin exhibit a reversible binding to Na+/K+-
ATPase, whereas the binding of CGs bearing sugar moiety is
irreversible and exhibits a different pharmacokinetics behav-
ior.38 Without sugar moieties present, the molecules
dissociated in the bloodstream much faster.36 This was further
supported by the findings of ref 39, which demonstrated that
125I-digoxin-iodohistamine(bis(O-carboxymethyloxime)) ex-
hibits selective myocardial accumulation in guinea pigs
compared with the 125I-digoxigenin-iodohistamine(3-oxime)
and 125I-digoxigenin-iodohistamine(3-ester). Like other imag-
ing probes already described, e.g., by de Barros and co-
workers,2 99mTc-DTPA−DIG showed a fast blood clearance
and a renal excretion. Therefore, its possible use as an imaging
probe is thereby further strengthened.
■ CONCLUSIONS
In conclusion, the compound DTPA−DIG was successfully
synthesized, characterized, and labeled with technetium-99m,
Figure 4. Binding of 99mTc-DTPA−DIG to MRC-5 non-tumor lung
cell lines and to A549 lung cancer cell lines after 2 h of incubation.
99mTc-DTPA−DIG showed significantly higher affinity to A549 lung
cancer cell lines. Specific binding was significantly reduced by 10-fold
blocking with free DIG. Results are expressed as a mean ± standard
error (n = 3).
Table 2. Biodistribution of 99mTc-DTPA−Digitoxigenin in
Healthy Mice Expressed as a Mean Percentage (n = 6) of the
Injected Dose/g (%ID/g) Tissue ± Standard Deviation
tissue 30 min (%ID/g) SD 2 h (%ID/g) SD
blood 0.51 0.08 0.43 0.16
liver 4.74 1.67 2.34 0.31
spleen 0.90 0.13 0.85 0.21
kidney 1.64 0.38 1.48 0.22
heart 0.31 0.05 0.32 0.29
lungs 1.46 0.35 0.6 0.17
thyroid 0.59 0.27 0.59 0.45
intestine 24.97 5.47 27.06 1.64
muscle 0.50 0.38 0.26 0.15
Figure 5. Blood clearance of 99mTc-DTPA−DIG in healthy mice (n =
6).
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showing a high level of stability. In vitro binding assays
confirmed a higher and specific affinity of 99mTc-DTPA−DIG
to non-small-cell lung cancer A549 cells in comparison to
human fetal lung fibroblast MRC-5 cells, probably due to the
specific binding of 99mTc-DTPA−DIG to the target Na+/K+-
ATPase. Neither the labeling solution nor DTPA inhibited
significantly the Na+/K+-ATPase activity. 99mTc-DTPA−DIG
blood levels decline fast, which allows obtaining early images.
In addition, biodistribution and scintigraphic studies showed a
high uptake by the intestine, liver and kidney. Taken together,
the results reported here demonstrate the specificity of 99mTc-
DTPA−DIG to lung cancer cells and suggest that this new
radiolabeled derivative might be potentially useful for imaging
techniques applied to diagnoses of tumors and other diseases
that show distinct expression rates of the Na+ /K+-ATPase.
■ MATERIAL AND METHODS
Material. 99mTc was acquired from a 99Mo/99m Tc
generator supplied by Instituto de Pesquisas Energet́icas e
NuclearesIPEN (Saõ Paulo, Brazil). Other reagents and
solvents for the radiolabeling procedure were purchased from
Sigma-Aldrich (Saõ Paulo, Brazil). The human non-small-cell
lung cancer A549 cell line (ATCC CCL-185) was obtained
from American Type Culture Collection (ATCC, Manassas,
VA). Human fetal lung fibroblast cells (MRC-5) were acquired
from the European Collection of Cell Cultures (ECACC,
Porton Down, WI, England). Dulbecco’s modified Eagle’s
medium (DMEM; Gibco, Waltham, MA) was used for cell
cultivation supplemented with fetal bovine serum (FBS)
purchased from Sigma-Aldrich (Saõ Paulo, Brazil). Antibiotics
penicillin and streptomycin were obtained from Sigma-Aldrich
(St. Louis, MO). Trypsin was acquired from Invitrogen (Saõ
Paulo, Brazil), and matrigel was obtained from Becton,
Dickinson and Company-BD (Juiz de Fora, Brazil). Female
BALB/c mice (15−20 g) were purchased from the central
vivarium at Universidade Federal de Minas Gerais. Animals
were kept under specific pathogen-free (SPF) conditions, with
free access to food and water. The cages were temperature-
controlled with filtered air and a regulated light−dark cycle
(12:12 h). All protocols were approved by the Ethics
Committee for Animal Experiments at Universidade Federal
de Minas Gerais (protocol number 424/2014) and are in
compliance with the guide for the care and use of laboratory
animals recommended by the Institute of Laboratory Animal
Resources.
Synthesis of the DTPA−DIG Compound. The reaction
was performed in a preparative scale with DMSO as the
solvent. First, 110 mg of digitoxigenin (0.29 mmol), 550 mg of
DTPA dianhydride (1.54 mmol), and 27.5 mg of DMAP (0.22
mmol), used as the catalyst, were added to a cylindrical tube
(13.5 × 3.5 cm2). Then, 5.5 mL of DMSO was added, and the
reaction mixture was heated to 65 ± 2 °C under calcium
chloride protection by using a drying tube to create a water-
free environment. The mixture was stirred for 8 h. Next, the
reaction mixture was maintained for 48 h at 8 °C and then
subjected to purification procedures.
Isolation of DTPA−DIG by Semipreparative RP-HPLC.
DTPA−DIG was isolated by semipreparative RP-HPLC using
a Shimadzu equipment (Shimadzu Corp., Japan) composed of
wo LC6AD pumps and a manual injection valve (Rheodyne
7125, Rheodyne, CO). The injection was performed using a
1.000 μL sample loop, and detection was carried out at 200
and 220 nm, employing a dual-wavelength detector (SPD
M10A) controlled by LCsolution software v.1.25 (Shimadzu
Corp.). Separation was performed on an ODS column (Shim-
pack PREP-ODS; 250 × 4.6 mm2 i.d., 5 μm), using a linear
gradient of 10−100% ACN with 0.1% formic acid (v/v) for
elution in 20 min, at a flow rate of 7 mL/min. The obtained
peak fractions were pooled, and the acetonitrile was removed
in a rotary evaporator at 30 °C, followed by lyophilization to
eliminate the water.
Infrared Spectroscopy. The IR spectrum was recorded on
a PerkinElmer Spectrum One spectrometer (Beaconsfield,
U.K.) with an attenuated total reflection (ATR) system.
NMR Analysis. 1H NMR, 13C NMR, DEPT-135, 1H−1H
COSY, HSQC, HMBC, and NOESY spectra were recorded on
a Bruker DRX-400 spectrometer (1H 400 MHz and 13C 100
MHz) in DMSO-d6 at 300 K with tetramethylsilane (TMS) as
the internal standard for both nuclei. Chemical shifts (δ) are
given in ppm and J couplings in hertz (Hz).
Radiolabeling and Radiochemical Purity of DTPA−
DIG with Technetium-99m. First, 1 mg of the DTPA−DIG
(1.3 nmol) was dissolved in 20 μL of DMSO and diluted with
380 μL of saline. Then, 100 μL of a 1 mg/mL solution of
stannous chloride (in HCl 0.25 M), as a reducing agent, was
added. The pH of the solution was adjusted to 7 with a NaOH
solution (140 μL of 0.1 M), and the vial was immediately
vacuum-sealed. Pertechnetate (99mTcO4
−) was added (∼3
mCi), and the mixture was allowed to react for 15 min at room
temperature (23 °C). The radiolabeling yields of the 99mTc-
DTPA−DIG were determined by thin-layer chromatography
(TLC) analysis on two solvent systems: acetone to determine
99mTcO4
− and glacial acetic acid/water (15:85) to determine
99mTcO2. The radioactivity of centered cut TLCs was
measured using an automatic scintillation counter.
An additional staining with Kedde’s reagent was carried out
for proving the stability of the DTPA−DIG by detection of the
lactone ring after radiolabeling.
UPLC/MS Analysis of Radiolabeling. UPLC/MS anal-
yses were carried out on an ACQUITY Ultra Performance LC
system (Waters, Milford, MA) linked simultaneously to a
photodiode array detector (PDA) 2996 photodiode array
detector (Waters, Milford, MA) and an ACQUITY TQ
Detector (Waters MS Technologies, Manchester, U.K.),
equipped with a Z-spray electrospray ionization (ESI) source
operating in positive and negative modes. MassLynx software
(version 4.1, Waters, Milford, MA) was used to control the
instruments, as well as for data acquisition and processing.
Diluted sample solutions (3 μL; 0.5 mg/mL; 0.58 nmol) were
injected into a reversed-phase column (BEHC18, 1.7 μm, 1 ×
50 mm2, Waters, Milford, MA), which was maintained at 40
°C. The mobile phase consisted of solvent A (H2O/0.1
HCOOH) and solvent B (acetonitrile/0.1 HCOOH) at a flow
rate of 300 μL/min, eluted in a linear gradient, as follows: T =
0 min, 5% B; T = 10 min, 95% B; T = 11 min, 5% B; T = 13
min, 5% B. The effluent was introduced into a PDA detector
(scanning range 210−400 nm, resolution 1.2 nm) and
subsequently into an electrospray source (source block
temperature 120 °C, desolvation temperature 350 °C, capillary
voltage 3.5 kV, cone voltage 30 V) and nitrogen as the
desolvation gas (600 L/h). Mass chromatograms were
recorded in the positive and negative ionization modes.
In Vitro Stability. Radiochemical stability was evaluated in
saline at room temperature and in plasma at 37 °C, under
agitation, from samples taken 1, 2, 4, 8, and 24 h after
incubation at room temperature (23 °C). Radiochemical
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stability was determined by TLC as described above. The
radioactivity was measured using an automatic scintillation
counter. The number of samples per each time point was 6,
and they were evaluated in duplicates.
Binding of the Radiolabeled Compound towards
MRC-5 and A549 Cell Lines. Cell Culture. Human non-
small-cell lung cancer (A549) and human fetal lung fibroblast
cells (MRC-5) were cultured in DMEM supplemented with
10% (v/v) fetal bovine serum and 1% (v/v) penicillin and
streptomycin as antibiotics. Cells were maintained in a
humidified incubator with a 5% CO2 atmosphere at 37 °C.
The cells were grown to confluence and then harvested by
trypsin dissociation. After centrifugation (500g for 5 min), cells
were resuspended with a phosphate-buffered saline (PBS)
solution (pH 7.4). Viable cells for the binding assays were
quantified using trypan blue staining, and cell number was
countered in a Neubauer Chamber.
Cell Viability. The colorimetric MTT assay was performed
using 3-(4,5-dimethyl-1,3-thiazole-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT). Cells (1 × 104 A549 and MRC-5
cells per well of a 96-well microtiter plate) were cultured for 48
h with various concentrations of 99mTc-DTPA−DIG. At the
indicated time points, MTT was added to a final concentration
of 1 mg/mL, and 200 μL of DMSO was added after 4 h of
incubation at 37 °C to dissolve the formazan crystals. The
absorbance was measured at 570 nm using a plate
spectrophotometer (VersaMax ELISA Microplate Reader,
Molecular Devices). Cells treated with 0.5% DMSO served
as a negative control to define 100% viability. The percentage
of viable cells was plotted against the sample concentration,
and the IC50 values were determined based on the dose−
response curves using GraphPad Prism 5.0 (GraphPad
software, La Jolla, CA).
Na+/K+-ATPase Assay. Enzymatic activities of the Na+/K+-
ATPase α1,2,3 subunit of the porcine cortex (Sigma) were
assayed using 4 mM ATP as the substrate in a final volume of
40 μL assay buffer containing 40 mM Tris−HCl pH 7.5, 80
mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA),
and 8 mM MgAc2. The negative control was assayed without
enzyme, and 4 mM ATP was added after 30 min of incubation
at room temperature. The positive control contained 0.05 U/
mL Na+/K+-ATPase α1,2,3 subunits of the porcine cortex in a
30 min preincubated mixture with assay buffer; later, 4 mM
ATP was added. Inhibition assays were performed by co-
incubating the enzyme and individual inhibitor at concen-
trations of 0.1 μM for 30 min and adding 4 mM ATP solution.
Reactions were stopped after 30 min of incubation, and activity
was determined by measuring the Pi released according to the
malachite-green test40 Activity was scored as the percentage of
reduction of absorbance subtracting the absorbance at 600 nm
of the control well, relative to the positive control well. Positive
control defined 100% enzyme activity. All experiments were
performed in triplicates.
Binding Studies. For the binding assay, 0.1 μM of the
99mTc-DTPA−DIG, 1.3 μM of 99mTc-DTPA, and 99mTc-
DTPA−DIG with excess (10-times) of free digitoxigenin
were incubated at 37 °C with 250 000 viable cells/tube. This
mixture was kept under agitation (140 rpm) for 120 min. Next,
the material was centrifuged at 10 000 g for 5 min and the
supernatant discarded. The pellet was resuspended in 500 μL
of PBS and analyzed in an automatic scintillation counter. The
experiment was performed in independent biological triplicates
each consisting of three technical replicates.
In Vivo Studies in Healthy Mice. Blood Clearance.
Aliquots of 100 μL (3.7 MBq) of the diluted 99mTc-DTPA−
DIG (final volume 1800 μL) were administrated to healthy
BALB/c female mice (20 g, 8 weeks old, n = 6, per time point)
through the tail vein and blood samples were extracted 5, 15,
30, 60, 120, and 240 min after administration. Each sample was
weighted, and the associated radioactivity was determined. The
percentage of injected dose per milliliter of blood (%ID/mL)
was determined, and the data were plotted as a function of
time.
Biodistribution. Aliquots of 100 μL (3.7 MBq) of the
diluted 99mTc-DTPA−DIG (final volume 1800 μL) were
injected intravenously into healthy BALB/c mice (20 g, 8
weeks old, n = 6, six per time point). After 30 min or 2 h, mice
were anesthetized (ketamine: 80 mg/kg; xylazine: 15 mg/kg)
and euthanatized. Blood, liver, spleen, kidney, heart, lungs,
muscle, thyroid, and intestine were removed, dried on filter
paper, and placed in preweighed plastic test tubes. The
radioactivity was measured. A standard dosage containing the
same injected amount was counted simultaneously in a
separate tube, which was defined as 100% radioactivity. The
results were expressed as the percentage of injected dose/g of
tissue (%ID/g).
Scintigraphic Images. First, 100 μL aliquots (18 MBq) of
the diluted 99mTc-DTPA−DIG (dilution to final volume 3600
μL) were injected intravenously into the tail vein of healthy
BALB/c mice (20 g, 8 weeks old, n = 6 per time point). After
30 min, 1 h, and 2 h, mice were anesthetized (ketamine: 80
mg/kg; xylazine: 15 mg/kg) and placed horizontally under the
collimator of a low-energy high-resolution γ camera (Mediso,
Hungary). Images were acquired using a 256 × 256 × 16
matrix size with a 20% energy window set at 140 keV for a
period of 300 s.
Statistical Analysis. All data were expressed as mean ±
standard deviation of the mean. Means between the various
groups were compared by one-way analysis of variance
(ANOVA followed by Tukey’s post hoc test). In the case of
multiple comparisons, a post hoc Bonferroni correction was
applied. P values <0.001 were considered statistically
significant. Data were analyzed using GraphPad Prism 5
Software (GraphPad, San Diego, CA).
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